Evidence map›Paper›PMID 18155964›Full record

Trial reportClinical immunology (Orlando, Fla.)2008

Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly.

Ivan K Chinn, Blythe H Devlin, Yi-Ju Li, M Louise Markert

8 registry-linked trialsOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Clinical immunology (Orlando, Fla.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 8 registered trials, which are not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00566488 phase1completednot on this map

Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2005 to 2019Enrolled25ConditionsDiGeorge Syndrome, Hypoparathyroidism, Complete DiGeorge SyndromeArmsThymus/Parathyroid Transplantation
NCT00576407 phase2completednot on this map

Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan1991 to 2017Enrolled26ConditionsDiGeorge Syndrome, Complete Typical DiGeorge AnomalyArmsCultured Thymus Tissue for Implantation (CTTI)
NCT00576836 phase2completednot on this map

Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2004 to 2019Enrolled7ConditionsDiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge SyndromeArmsCultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation
NCT00579527 phase1 / phase2completednot on this map

Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2005 to 2017Enrolled14ConditionsDiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge SyndromeArmsCultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine
NCT00579709 phase1completednot on this map

Thymus Transplantation With Immunosuppression, #884

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2002 to 2019Enrolled15ConditionsDiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete DiGeorge SyndromeArmsThymus Tissue for Transplantation
NCT00849888 phase1terminatednot on this map

Phase I Serum-Free Cultured Thymus Transplantation in DiGeorge Anomaly, IND9836

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2008 to 2011Enrolled2ConditionsDiGeorge AnomalyArmsSerum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression
NCT01220531 nacompletednot on this mapstarted 2010, after this paper: background citation

Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2010 to 2023Enrolled29ConditionsComplete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge SyndromeArmsCultured Thymus Tissue
NCT02274662 phase4completednot on this mapstarted 2014, after this paper: background citation

Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2014 to 2023Enrolled11ConditionsPoor Thymic Function, Immunodeficiency, Athymia, ImmunoreconstitutionArmsCultured Thymus Tissue, Blood Draw, Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Immunological aspects of 22q11.2 deletion syndrome.Cellular and molecular life sciences : CMLS · 2012
    Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Ivan K ChinnDepartment of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA. chinn001@mc.duke.edu
Blythe H Devlin
Yi-Ju Li
M Louise Markert
Duke University Hospital · USCenter for Human Genetics · USDuke Medical Center · US

Funding

Pilot Project for the DTMI CRA ProgramUL1RR024128 · NCRR · DUKE UNIVERSITY · PI CALIFF, ROBERT M · 2006 to 2010
$48.1M
XOMAZYME-CD5 PLUS THERAPY IN RHEUMATOID ARTHRITISM01RR000030 · NCRR · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 1985 to 2006
$20.0M
THYMIC TRANSPLANTATION IN COMPLETE DIGEORGE SYNDROMER01AI047040 · NIAID · DUKE UNIVERSITY · PI MARKERT, M. LOUISE · 1999 to 2014
$8.0M
RESEARCH TRAINING IN ALLERGY AND CLINICAL IMMUNOLOGYT32AI007062 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David B. Peden, John W. Sleasman · 1985 to 2026
$6.1M
Center for Molecular &Cellular Studies of Ped DiseaseK12HD043494 · NICHD · DUKE UNIVERSITY · PI REED, ANN M. · 2003 to 2017
$5.2M
Parathyroid and Thymus Transplants in DiGeorge SyndromeR21AI060967 · NIAID · DUKE UNIVERSITY · PI MARKERT, MARY LOUISE · 2004 to 2005
$396k
NCRR NIH HHS M01 RR000030NCRR NIH HHS U54 RR 023469NCRR NIH HHS UL1 RR024128NIAID NIH HHS R01 AI047040NIAID NIH HHS R01 AI 47040NIAID NIH HHS R21 AI060967NIAID NIH HHS T32 AI007062NIAID NIH HHS T32 AI 007062-28A2NICHD NIH HHS K12 HD043494
6 · The paper itself

Abstract

Thymus transplantation in subjects with complete DiGeorge anomaly using postnatal allogeneic HLA-nonmatched cultured thymus tissue provides immunoreconstitution. Tolerance of the newly developed T cells toward the donor thymus has not previously been studied. Mixed lymphocyte cultures were used to test 12 thymus transplant recipients for long-term tolerance toward their thymus allografts. Two subjects tested for responses toward thymus donor peripheral blood mononuclear cells showed significantly less reactivity toward the donors compared to responses against third-party allogeneic cells. Peripheral blood mononuclear cells from 10 other subjects were less responsive toward cryopreserved donor thymic cells than toward allogeneic cells (P=0.00007). Adult control peripheral blood mononuclear cells proliferated strongly in response to the donor thymic cells. Both the subjects and controls showed similar proliferative responses against allogeneic cells and phytohemagglutinin. This study provides in vitro evidence for long-term tolerance of complete DiGeorge anomaly thymus transplantation recipients toward their HLA-nonmatched thymus grafts.

Indexed as

DiGeorge SyndromeFemaleHumansInfantMaleThymus GlandTime FactorsTissue DonorsTransplantation, HomologousTransplantation Tolerance

Identifiers

PMID18155964
PMCPMC2562745
OpenAlexW2035519735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 2 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.